Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Infant Formula Recall Regulations, 22885-22886 [05-8766]
Download as PDF
<![CDATA[
22885
Federal Register / Vol. 70, No. 84 / Tuesday, May 3, 2005 / Notices
Dated: April 26, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–8738 Filed 5–2–05; 8:45 am]
has submitted the following proposed
collection of information to OMB for
review and clearance.
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0029]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Infant Formula
Recall Regulations
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by June 2,
2005.
ADDRESSES: OMB is still experiencing
significant delays in the regular mail,
including first class and express mail,
and messenger deliveries are not being
accepted. To ensure that comments on
the information collection are received,
OMB recommends that comments be
faxed to the Office of Information and
Regulatory Affairs, OMB, Attn: Fumie
Yokota, Desk Officer for FDA, FAX:
202–395–6974.
FOR FURTHER INFORMATION CONTACT:
Peggy Robbins, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1223.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
Infant Formula Recall Regulations—21
CFR 107.230, 107.240, 107.250, 107.260,
107.280 (OMB Control Number 0910–
0188)—Extension
Section 412(e) of the Federal Food,
Drug, and Cosmetic Act (the act) (21
U.S.C. 350a(e)) provides that if the
manufacturer of an infant formula has
knowledge that reasonably supports the
conclusion that an infant formula
processed by that manufacturer has left
its control and may not provide the
nutrients required in section 412(i) of
the act or is otherwise adulterated or
misbranded, the manufacturer must
promptly notify the Secretary of Health
and Human Services (the Secretary). If
the Secretary determines that the infant
formula presents a risk to human health,
the manufacturer must immediately take
all actions necessary to recall shipments
of such infant formula from all
wholesale and retail establishments,
consistent with recall regulations and
guidelines issued by the Secretary.
Section 412(f)(2) of the act states that
the Secretary shall by regulation
prescribe the scope and extent of recalls
of infant formula necessary and
appropriate for the degree of risk to
human health presented by the formula
subject to recall. FDA’s infant formula
recall regulations (part 107 (21 CFR part
107), subpart E) implement these
statutory provisions.
Section 107.230 requires each
recalling firm to conduct an infant
formula recall with the following
elements: (1) Evaluate the hazard to
human health, (2) devise a written recall
strategy, (3) promptly notify each
affected direct account (customer) about
the recall, and (4) furnish the
appropriate FDA district office with
copies of these documents. If the
recalled formula presents a risk to
human health, the recalling firm must
also request that each establishment that
sells the recalled formula post (at point
of purchase) a notice of the recall and
provide FDA with a copy of the notice.
Section 107.240 requires the recalling
firm to conduct an infant formula recall
with the following elements: (1) Notify
the appropriate FDA district office of
the recall by telephone within 24 hours,
(2) submit a written report to that office
within 14 days, and (3) submit a written
status report at least every 14 days until
the recall is terminated. Before
terminating a recall, the recalling firm is
required to submit a recommendation
for termination of the recall to the
appropriate FDA district office and wait
for written FDA concurrence
(§ 107.250). Where the recall strategy or
implementation is determined to be
deficient, FDA may require the firm to
change the extent of the recall, carry out
additional effectiveness checks, and
issue additional notifications
(§ 107.260). In addition, to facilitate
location of the product being recalled,
the recalling firm is required to
maintain distribution records for at least
1 year after the expiration of the shelf
life of the infant formula (§ 107.280).
The reporting and recordkeeping
requirements described previously are
designed to enable FDA to monitor the
effectiveness of infant formula recalls in
order to protect babies from infant
formula that may be unsafe because of
contamination or nutritional inadequacy
or otherwise adulterated or misbranded.
FDA uses the information collected
under these regulations to help ensure
that such products are quickly and
efficiently removed from the market.
In the Federal Register of February 1,
2005 (70 FR 5188), FDA published a 60day notice requesting public comment
on the information collection
provisions. No comments were received.
FDA estimates the burden of the
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
21 CFR section
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total Hours
107.230
2
1
2
4,500
9,000
107.240
2
1
2
1,482
2,964
107.250
2
1
2
120
240
107.260
1
1
1
650
650
Total
1 There
12,854
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate jul<14>2003
15:43 May 02, 2005
Jkt 205001
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
E:\FR\FM\03MYN1.SGM
03MYN1
22886
Federal Register / Vol. 70, No. 84 / Tuesday, May 3, 2005 / Notices
Under 5 CFR 1320.3(b)(2), the time,
effort, and financial resources necessary
to comply with a collection of
information are excluded from the
burden estimate if the reporting,
recordkeeping, or disclosure activities
needed to comply are usual and
customary because they would occur in
the normal course of activities. No
burden has been estimated for the
recordkeeping requirement in § 107.280
because these records are maintained as
a usual and customary part of normal
business activities. Manufacturers keep
infant formula distribution records for
the prescribed period as a matter of
routine business practice.
The reporting burden estimate is
based on agency records, which show
that there are five manufacturers of
infant formula and that there have been,
on average, two infant formula recalls
per year for the past 3 years.
Dated: April 26, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–8766 Filed 5–2–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0031]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Premarket
Notification for a New Dietary
Ingredient
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by June 2,
2005.
ADDRESSES: OMB is still experiencing
significant delays in the regular mail,
including first class and express mail,
and messenger deliveries are not being
accepted. To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: Fumie Yokota, Desk Officer
for FDA, FAX: 202–395–6974.
FOR FURTHER INFORMATION CONTACT:
Peggy Robbins, Office of Management
Programs (HFA 250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1223.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Premarket Notification for a New
Dietary Ingredient—21 CFR 190.6
(OMB Control Number 0910–0330)—
Extension
Section 413(a) of the Federal Food,
Drug, and Cosmetic Act (the act) (21
U.S.C. 350b(a)) provides that a
manufacturer or distributor of dietary
supplements or of a new dietary
ingredient is to submit information to
FDA (as delegate for the Secretary of
Health and Human Services) upon
which it has based its conclusion that a
dietary supplement containing a new
dietary ingredient will reasonably be
expected to be safe at least 75 days
before the introduction or delivery for
introduction into interstate commerce of
a dietary supplement that contains a
new dietary ingredient. FDA’s
regulations at part 190, subpart B (21
CFR part 190, subpart B) implement
these statutory provisions. Section
190.6(a) requires each manufacturer or
distributor of a dietary supplement
containing a new dietary ingredient, or
of a new dietary ingredient, to submit to
the Office of Nutritional Products,
Labeling, and Dietary Supplements
notification of the basis for their
conclusion that said supplement or
ingredient will reasonably be expected
to be safe. Section 190.6(b) requires that
the notification include the following:
(1) The complete name and address of
the manufacturer or distributor, (2) the
name of the new dietary ingredient, (3)
a description of the dietary supplements
that contains the new dietary ingredient,
and (4) the history of use or other
evidence of safety establishing that the
dietary ingredient will reasonably be
expected to be safe.
The notification requirements
described previously are designed to
enable FDA to monitor the introduction
into the food supply of new dietary
ingredients and dietary supplements
that contain new dietary ingredients, in
order to protect consumers from unsafe
dietary supplements. FDA uses the
information collected under these
regulations to help ensure that a
manufacturer or distributor of a dietary
supplement containing a new dietary
ingredient is in full compliance with the
act.
In the Federal Register of February 7,
2005 (70 FR 6444), FDA published a 60day notice requesting public comment
on the information collection
provisions. No comments were received.
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
21 CFR Section
190.6
1 There
Annual Frequency
per Response
71
Total Annual
Responses
1
Hours per
Respondent
71
Total Hours
20
1,420
are no capital costs or operating and maintenance costs associated with this collection of information.
The agency believes that there will be
minimal burden on the industry to
generate data to meet the requirements
of the premarket notification program,
because the agency is requesting only
that information that the manufacturer
or distributor should already have
developed to satisfy itself that a dietary
supplement containing a new dietary
ingredient is in full compliance with the
VerDate jul<14>2003
15:43 May 02, 2005
Jkt 205001
act. However, the agency estimates that
extracting and summarizing the relevant
information from the company’s files,
and presenting it in a format that will
meet the requirements of section 413 of
the act, will require a burden of
approximately 20 hours of work per
submission.
During the past 3 fiscal years, from
October 1, 2002, through September 30,
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
2004, FDA received an average of 47
notifications per year with an average of
1 notification per submitting
manufacture or distributor. In
comparison, during the previous 3 fiscal
years, from October 1, 1999, through
September 30, 2001, FDA received an
average of 23 notifications per year with
an average of 1 notification per
submitter. The annual average number
E:\FR\FM\03MYN1.SGM
03MYN1
]]>Agencies
[Federal Register Volume 70, Number 84 (Tuesday, May 3, 2005)]
[Notices]
[Pages 22885-22886]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-8766]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N-0029]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Infant Formula Recall
Regulations
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by June 2,
2005.
ADDRESSES: OMB is still experiencing significant delays in the regular
mail, including first class and express mail, and messenger deliveries
are not being accepted. To ensure that comments on the information
collection are received, OMB recommends that comments be faxed to the
Office of Information and Regulatory Affairs, OMB, Attn: Fumie Yokota,
Desk Officer for FDA, FAX: 202-395-6974.
FOR FURTHER INFORMATION CONTACT: Peggy Robbins, Office of Management
Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-1223.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Infant Formula Recall Regulations--21 CFR 107.230, 107.240, 107.250,
107.260, 107.280 (OMB Control Number 0910-0188)--Extension
Section 412(e) of the Federal Food, Drug, and Cosmetic Act (the
act) (21 U.S.C. 350a(e)) provides that if the manufacturer of an infant
formula has knowledge that reasonably supports the conclusion that an
infant formula processed by that manufacturer has left its control and
may not provide the nutrients required in section 412(i) of the act or
is otherwise adulterated or misbranded, the manufacturer must promptly
notify the Secretary of Health and Human Services (the Secretary). If
the Secretary determines that the infant formula presents a risk to
human health, the manufacturer must immediately take all actions
necessary to recall shipments of such infant formula from all wholesale
and retail establishments, consistent with recall regulations and
guidelines issued by the Secretary. Section 412(f)(2) of the act states
that the Secretary shall by regulation prescribe the scope and extent
of recalls of infant formula necessary and appropriate for the degree
of risk to human health presented by the formula subject to recall.
FDA's infant formula recall regulations (part 107 (21 CFR part 107),
subpart E) implement these statutory provisions.
Section 107.230 requires each recalling firm to conduct an infant
formula recall with the following elements: (1) Evaluate the hazard to
human health, (2) devise a written recall strategy, (3) promptly notify
each affected direct account (customer) about the recall, and (4)
furnish the appropriate FDA district office with copies of these
documents. If the recalled formula presents a risk to human health, the
recalling firm must also request that each establishment that sells the
recalled formula post (at point of purchase) a notice of the recall and
provide FDA with a copy of the notice. Section 107.240 requires the
recalling firm to conduct an infant formula recall with the following
elements: (1) Notify the appropriate FDA district office of the recall
by telephone within 24 hours, (2) submit a written report to that
office within 14 days, and (3) submit a written status report at least
every 14 days until the recall is terminated. Before terminating a
recall, the recalling firm is required to submit a recommendation for
termination of the recall to the appropriate FDA district office and
wait for written FDA concurrence (Sec. 107.250). Where the recall
strategy or implementation is determined to be deficient, FDA may
require the firm to change the extent of the recall, carry out
additional effectiveness checks, and issue additional notifications
(Sec. 107.260). In addition, to facilitate location of the product
being recalled, the recalling firm is required to maintain distribution
records for at least 1 year after the expiration of the shelf life of
the infant formula (Sec. 107.280).
The reporting and recordkeeping requirements described previously
are designed to enable FDA to monitor the effectiveness of infant
formula recalls in order to protect babies from infant formula that may
be unsafe because of contamination or nutritional inadequacy or
otherwise adulterated or misbranded. FDA uses the information collected
under these regulations to help ensure that such products are quickly
and efficiently removed from the market.
In the Federal Register of February 1, 2005 (70 FR 5188), FDA
published a 60-day notice requesting public comment on the information
collection provisions. No comments were received.
FDA estimates the burden of the collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR section Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
107.230 2 1 2 4,500 9,000
----------------------------------------------------------------------------------------------------------------
107.240 2 1 2 1,482 2,964
----------------------------------------------------------------------------------------------------------------
107.250 2 1 2 120 240
----------------------------------------------------------------------------------------------------------------
107.260 1 1 1 650 650
----------------------------------------------------------------------------------------------------------------
Total 12,854
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
[[Page 22886]]
Under 5 CFR 1320.3(b)(2), the time, effort, and financial resources
necessary to comply with a collection of information are excluded from
the burden estimate if the reporting, recordkeeping, or disclosure
activities needed to comply are usual and customary because they would
occur in the normal course of activities. No burden has been estimated
for the recordkeeping requirement in Sec. 107.280 because these
records are maintained as a usual and customary part of normal business
activities. Manufacturers keep infant formula distribution records for
the prescribed period as a matter of routine business practice.
The reporting burden estimate is based on agency records, which
show that there are five manufacturers of infant formula and that there
have been, on average, two infant formula recalls per year for the past
3 years.
Dated: April 26, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-8766 Filed 5-2-05; 8:45 am]
BILLING CODE 4160-01-S
